CYFRA<sup>21-1</sup>、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析

金秀木; 谢文晖; 俞志昌; 张佩玲

doi:null

您当前的位置：

首页 >

文章列表页 >

CYFRA^21-1、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析

更新时间：2021-03-12

- CYFRA^21-1、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析
- Clinical study of combined determination of CYFRA^21-1, CEA, NSE in the patients with lung cancer ──A retrospective analyses in 239 cases
- 核技术 2000年第11期
- 作者机构：
  
  上海市胸科医院,上海,200030
- 作者简介：
- 基金信息：
- DOI：
  中图分类号：
- 纸质出版日期：2000-11-01
- 稿件说明：
移动端阅览
[1]金秀木,谢文晖,俞志昌,张佩玲.CYFRA~(21-1)、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析[J].核技术,2000(11):800-804.

JIN Xiumu, XIE Wenhui, YU Zhichang, et al. Clinical study of combined determination of CYFRA^21-1, CEA, NSE in the patients with lung cancer ──A retrospective analyses in 239 cases[J]. Nuclear techniques, 2000, (11): 800-804.
[1]金秀木,谢文晖,俞志昌,张佩玲.CYFRA~(21-1)、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析[J].核技术,2000(11):800-804. DOI：

JIN Xiumu, XIE Wenhui, YU Zhichang, et al. Clinical study of combined determination of CYFRA^21-1, CEA, NSE in the patients with lung cancer ──A retrospective analyses in 239 cases[J]. Nuclear techniques, 2000, (11): 800-804. DOI：

摘要

测定了２３９例肺癌病人（其中腺癌１２９例，鳞癌５９例，小细胞癌３５例，腺、鳞癌混合型癌１６例）和６６例其它肺疾患病人胸水和血清中骨胶素（ＣＹＦＲＡ２１－２）、癌胚抗原（ＣＥＡ）、烯醇化酶（ＮＳＥ）的浓度。结果显示：三项测定的总阳性率依次是ＣＹＦＲＥ２１－１为５１．４％，ＣＥＡ４３．５％，ＮＳＥ４８．１％，但与病理类型相关，鳞癌以ＣＹＦＲＡ２１－１最高为７６．３％，腺癌以ＣＥＡ最高达５７．１％，而小细胞肺癌则以ＮＳＥ最高达９４．３％。４９例伴有胸水患者（腺癌２７例、小细胞肺癌７例、其它良性肺疾患１５例）的胸水和血清三项测定结果显示腺癌病人的胸水样本ＣＹＦＲＡ２１－１和ＣＥＡ测定均较血清样本更灵敏，而小细胞肺癌病人胸水样本的ＮＳＥ测定具有极可靠的价值。比较三项测定对不同病理类型癌症病人的敏感性和特异性在非癌症的其它肺疾病患者中的假阳性和假阴性，并进一步讨论三项联合测定的临床意义和必要性。

Abstract

Three tumor markers or CEA

CYFRA21-2 and NSE were assayed in 239 cases with lung cancer (adenocarcinoma 129

squamous-cell carcinoma 59

small cell lung cancer 35

mixed type of adenocarcinoma and squamous-cell carcinoma 16) and 66 cases with benign lung disease. The positive rate of CEA

CYFRA21-1 and NSE for detecting lung cancer were 51.4%

43.5% and 48.1% respectively. It seemed there was a relationship between the sensitivity and the pathologic patterns of lung cancer. The highest diagnostic sensitivities were 76.3% for CYFRA21-1 in the detection of squamous-cell carcinoma

57.4% for CEA in adenocarcinoma and 94.3% for NSE in the small cell lung cancer respectively. In 49 cases with pleural effusion (adenocarcinoma 27

small cell lung cancer 7

benign disease 15)

three tumor markers in serum and pleural fluid were both measued. The results indicated that the sensitivity of the CEA and CYFRA21-1 in pleural fluid in patients /with adenocarcinoma was superior to serum. The detection of the NSE in pleural fluid was a very reliable method in diagnosing the small cell lung cancer. The sensitivity and specificity of CEA

CYFRA21-1 and NSE in different pathologic patterns of lung cancer was compared and also the false positive and false negative in benign lung disease. Moreover

the clinical role and necessity of combined determination were also discussed.

关键词

Keywords

references

浏览量

136

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

CYFRA21—1和CEA联检在肺癌诊断中的应用

¹³¹I标记贝伐单抗偶联载紫杉醇超顺磁性氧化铁纳米粒的制作及生物分布实验

PET标准化摄取值在肺癌诊断中的价值及其影响因素的探讨

肿瘤标志物联合检测在肺癌诊断中的临床价值

血清酸性铁蛋白测定对肿瘤诊断价值的探讨

CYFRA21-1、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析

Clinical study of combined determination of CYFRA21-1, CEA, NSE in the patients with lung cancer ──A retrospective analyses in 239 cases

DOI：

摘要

Abstract

关键词

Keywords

references

CYFRA^21-1、CEA、NSE三项联合测定对肺癌患者的临床研究──239例肺癌病人的回顾性分析

Clinical study of combined determination of CYFRA^21-1, CEA, NSE in the patients with lung cancer ──A retrospective analyses in 239 cases